The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma
Open Access
- 1 September 2008
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 16 (9) , 1637-1642
- https://doi.org/10.1038/mt.2008.143
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trialThe Lancet Oncology, 2008
- Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963Journal of Clinical Investigation, 2007
- Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood FlowMolecular Therapy, 2007
- History of Oncolytic Viruses: Genesis to Genetic EngineeringMolecular Therapy, 2007
- Systemic Efficacy with Oncolytic Virus Therapeutics: Clinical Proof-of-Concept and Future DirectionsCancer Research, 2007
- Phase II Study of Sorafenib in Patients With Advanced Hepatocellular CarcinomaJournal of Clinical Oncology, 2006
- Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSFMolecular Therapy, 2006
- Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A regionCancer Gene Therapy, 2005
- Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity through Activation of NF-κBJournal of Virology, 2003
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalHepatology, 2003